Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Innoviva Inc (NQ: INVA )

11.35 +0.16 (+1.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 503,329
Open 11.13
Bid (Size) 11.14 (1)
Ask (Size) 11.58 (1)
Prev. Close 11.19
Today's Range 10.96 - 11.43
52wk Range 10.64 - 20.71
Shares Outstanding 68,126,089
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
From Innoviva, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Innoviva
 
Via Benzinga

Performance

YTD
-14.47%
-14.47%
1 Month
-7.57%
-7.57%
3 Month
-15.74%
-15.74%
6 Month
-4.38%
-4.38%
1 Year
-41.43%
-41.43%

More News

Read More
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Four Undervalued Healthcare Stocks for 2023
Via MarketBeat
Exposures COVID-19
Innoviva Earnings Perspective: Return On Capital Employed
Via Benzinga
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
From Innoviva, Inc.
Via Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
From Entasis Therapeutics Holdings Inc.
Via Globe NewsWire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
From Entasis Therapeutics Holdings Inc.
Via Globe NewsWire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Innoviva to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Innoviva, Inc.
Via Business Wire
3 No-Brainer Stocks Under $10 to Buy for September
Via InvestorPlace
Innoviva Completes Acquisition of La Jolla Pharmaceutical
From Innoviva, Inc.
Via Business Wire
Innoviva's Return On Capital Employed Overview
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Innoviva: Q2 Earnings Insights
Via Benzinga
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
From Innoviva, Inc.
Via Business Wire
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
Via Benzinga
Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment
From Innoviva, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.